My airport driver needs my flight number. Who needs the rest of the email?
An airport pickup shows how much personal data an AI booking service really needs, and what to ask before sharing a family itinerary.


A JOURNAL OF PERSPECTIVE
Progress gives us possibilities.
Perspective helps us choose.
Notes on health, money and the future—exploring what is changing, what we may have overlooked, and what it could mean for our lives.
TURN THE PERSPECTIVE
If we can detect more, what should we do differently?Fresh questions. Considered perspectives.
An airport pickup shows how much personal data an AI booking service really needs, and what to ask before sharing a family itinerary.
The firm is licensed. How do you check whether the person who sent the offer represents it?
What melanoma patients and investors can each learn from the same trial.
A pharmacy reading, a kaya toast excuse and one question to ask before you leave.
Three siblings split Mum’s clinic bill. What about the half-day’s pay her daughter gave up to take her?
A parent can keep the value of an investment private and still tell the family which broker to call.
Two parents can have the same EPF balance and very different room to give. What i-Legasi changes for EPF, for families and for your own retirement.
The reasoning behind Solve Everything, two real research examples, and what I take from a hopeful—but uncertain—medical future.
A fake interview was one entry point. My takeaway: security should allow for human mistakes and limit how far one breach can spread.
Humanoid robots invite us to imagine a future with more independence, better support—and perhaps someone else doing the washing-up.
Manufactured organs could expand our options. What separates a scientific breakthrough from a treatment a particular family can actually access?
Google Cloud revenue doubled, yet Alphabet shares fell. A closer look at growth, expectations and the cash needed to build AI’s future.
ER-100 brings new hope for restoring function. How should we think about longer lives when healthy years and care needs remain uncertain?
MediAsas invites a better comparison: what costs would a plan carry, what would our household retain, and could we sustain both through a difficult year?
A legacy needs a workable handover as well as valuable assets. Who could access cash, with what authority, and when?
AlphaGenome Atlas offers more promising research clues. My view on separating faster discovery from better outcomes—and asking who will be ready to benefit.
Earlier cancer detection offers a hopeful possibility: more time to understand, prepare and explore our options. What would help us make that time count?
A NOTE FROM THE EDITOR
“I’m interested in a brighter future.
And the questions that help us prepare for it.”
Hope and preparation belong in the same conversation. This journal makes room for both.
A little more about Risk Steward ↗Health & Longevity
Imagine having more time to understand an illness, explore treatment and make plans with the people who matter. That is the possibility that makes earlier cancer detection worth watching—and one reason I feel hopeful about where medicine is heading.

A screening result can point doctors toward further checks; it is not always a diagnosis. Screening can help find some diseases earlier, but it can also lead to false alarms, extra procedures or the detection of cancers that would never have caused harm. The right test depends on the person and the evidence behind it, so it is a decision to discuss with a doctor. [1]
The NHS-Galleri trial offers an encouraging lead to investigate: fewer stage IV cancers were observed in the screened group. The randomized study involved 142,250 people aged 50 to 77 across three screening rounds. The stage IV finding was a secondary outcome; the main outcome—reducing stage III and IV cancers combined across 12 prespecified cancer types—was not met. Further follow-up matters because a survival benefit has not yet been established. [2]
142,250
participants, aged 50–77
3
annual screening rounds
46–58%
of positive signals associated with a cancer diagnosis, depending on round
An encouraging signal: fewer stage IV cancers were observed in the screened group. This was a prespecified secondary outcome and gives researchers an important question to follow.
In context: the trial did not show a significant reduction in stage III + IV cancers combined across 12 prespecified cancer types. A survival benefit has not been established.
Screening signal → diagnostic checks → policy assessment. These are separate steps.
Source: Queen Mary University of London, 23 September 2026. The 46–58% figure concerns positive results, not the percentage of all cancers detected.
What interests me is the possibility of creating more room to act. If future research establishes that screening improves outcomes, earlier knowledge could become a valuable opportunity for families. The useful question is how we would turn that opportunity into informed decisions.
Critical illness cover is based on a contract. The policy’s definition, exclusions and other conditions determine how a claim is assessed. An earlier diagnosis does not automatically meet that definition, and different policies can treat early-stage illness differently. Bank Negara Malaysia advises consumers to read their policy terms and limitations carefully. [3]
I would ask three questions: what does my doctor recommend next; what support might my household need during further checks or treatment; and how would our savings and existing cover help? Understanding each answer gives us a clearer starting point. Check policy definitions, required evidence and any early-stage benefit with your insurer or adviser; the insurer assesses the claim.
For me, that is the hopeful part: a future with more useful information and more options—and families better prepared to make sense of both. A screening signal, a diagnosis and a payable claim remain different milestones; knowing the difference helps us plan with confidence.
Here is to science giving us more time. Perhaps we can spend a little of it reviewing the paperwork we have been meaning to get around to.
General education and personal commentary, not medical advice, a product recommendation or a decision on any claim.
[1] National Cancer Institute: Cancer Screening Overview
[2] NHS-Galleri randomized trial, New England Journal of Medicine (2026)
[3] Bank Negara Malaysia: Tips for Consumers
A QUESTION TO CARRY FORWARD
Original article ↗